BioCardia, Inc. cash flow to debt ratio of -1.41K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BioCardia, Inc.'s free cash flow has increased -7.33% from $-8.03M last year to $-7.44M, signaling increasing performance

BioCardia, Inc.'s debt to equity ratio is -0.39, signaling that the company spent its equity and risk bankruptcy.

BioCardia, Inc.'s debt to equity ratio is -0.39, signaling that the company spent its equity and risk bankruptcy.

BioCardia, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in BioCardia, Inc.'s latest filing, so interest coverage cannot be calculated.

BioCardia, Inc.'s profit margin has increased (-100.00%) in the last year from -13.70K% to 0.00%, signaling increasing performance

BioCardia, Inc.'s short-term assets of $2.73M exceed its short-term liabilities of $2.43M

BioCardia, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioCardia, Inc.'s return on equity of -5.46K%, is lower than 15.00%, indicating bad performance

BioCardia, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioCardia, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

BioCardia, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

BioCardia, Inc. has negative free cash flow, indicating cash burn

BioCardia, Inc.'s yearly earnings has decreased 3.55% since last year from $-7.95M to $-8.23M, signaling decreasing performance

BioCardia, Inc.'s yearly revenue has decreased 100.00% since last year from $58.00K to $0.00, signaling decreasing performance

ROIC 1.20K% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

BioCardia, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

BioCardia, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

BioCardia, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

BioCardia, Inc. has insufficient data to evaluate this check.

BioCardia, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioCardia, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BioCardia, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BioCardia, Inc. has insufficient data to evaluate this check.

BioCardia, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioCardia, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

BioCardia, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue